Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (661-670 of 713) with videos related to

Pageof 72
Sort By:
Plos One|May 17, 2014
Surveillance of Candida spp bloodstream infections: epidemiological trends and risk factors of death in two Mexican tertiary care hospitalsDora E Corzo-Leon, Tito Alvarado-Matute, Arnaldo L Colombo, et al.
Haematologica|March 13, 2025
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trialRichard F Schlenk, Pau Montesinos, Hee-Je Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaNaval Daver, Yanis Boumber, Hagop Kantarjian, et al.
The Lancet. Haematology|August 18, 2018
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trialTapan M Kadia, Jorge Cortes, Farhad Ravandi, et al.
Blood|August 5, 2017
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPNElias Jabbour, Nicholas J Short, Guillermo Montalban-Bravo, et al.
Blood Neoplasia|June 2, 2025
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trialTimothy S Pardee, Bayard L Powell, Richard A Larson, et al.
The Lancet. Oncology|June 4, 2018
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialJorge Cortes, Alexander E Perl, Hartmut Döhner, et al.
Blood|August 18, 2021
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trialJorge Cortes, Jane Apperley, Elza Lomaia, et al.
Cancer|October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutationsMahran Shoukier, Tapan Kadia, Marina Konopleva, et al.
Blood|October 27, 2007
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromesGuillermo Garcia-Manero, Hui Yang, Carlos Bueso-Ramos, et al.
Pageof 72

Showing results (661-670 of 713) with videos related to

Sort By:
Pageof 72
Plos One|May 17, 2014
Surveillance of Candida spp bloodstream infections: epidemiological trends and risk factors of death in two Mexican tertiary care hospitalsDora E Corzo-Leon, Tito Alvarado-Matute, Arnaldo L Colombo, et al.
Haematologica|March 13, 2025
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trialRichard F Schlenk, Pau Montesinos, Hee-Je Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaNaval Daver, Yanis Boumber, Hagop Kantarjian, et al.
The Lancet. Haematology|August 18, 2018
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trialTapan M Kadia, Jorge Cortes, Farhad Ravandi, et al.
Blood|August 5, 2017
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPNElias Jabbour, Nicholas J Short, Guillermo Montalban-Bravo, et al.
Blood Neoplasia|June 2, 2025
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trialTimothy S Pardee, Bayard L Powell, Richard A Larson, et al.
The Lancet. Oncology|June 4, 2018
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialJorge Cortes, Alexander E Perl, Hartmut Döhner, et al.
Blood|August 18, 2021
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trialJorge Cortes, Jane Apperley, Elza Lomaia, et al.
Cancer|October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutationsMahran Shoukier, Tapan Kadia, Marina Konopleva, et al.
Blood|October 27, 2007
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromesGuillermo Garcia-Manero, Hui Yang, Carlos Bueso-Ramos, et al.
Pageof 72